Progenics, Wyeth in drug partnership
-
- May
- 14
Progenics Pharmaceuticals Inc., an Eastview-based biotechnology research company, and Wyeth Pharmaceuticals said today that Wyeth applied to regulators in Europe for permission to market a drug for constipation caused by certain types of pain medicines.
The companies said Wyeth applied to the European Medicines Agency for marketing rights for methylnaltrexone. Progenics submitted the same application to the U.S. Food and Drug Administration in March.
Submission to the European regulators means Progenics receives a $4 million payment from Wyeth.
This entry was posted
on Monday, May 14th, 2007 at 6:00 pm by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: 
| 
Print
| 
Email
